MTX COVAB
Alternative Names: COVAB-36; MTX-COVABLatest Information Update: 01 Dec 2022
At a glance
- Originator Memo Therapeutics
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I COVID 2019 infections
Most Recent Events
- 02 Nov 2022 Memo Therapeutics completes the phase I trial in Covid-2019 infections (In volunteers) in Australia (IV) (NCT05351437)
- 26 Apr 2022 Phase-I clinical trials in COVID-2019 infections (In volunteers) in Australia (IV) (NCT05351437)
- 13 Dec 2021 Memo therapeutics plans phase I trials in COVID-2019 infections in the first quarter of 2022